{"denoms":[{"counts":[{"groupId":"BG000","value":"9"}],"units":"Participants"}],"groups":[{"description":"Induction Phase: 8 cycles (cycle length of 28 days)\n\n* Daratumumab SC:\n\n  1800mg SC weekly for 8 weeks for Cycle 1 and 2 1800mg SC every 2 weeks on Day 1 and 15 for Cycle 3-6 1800mg SC every 4 weeks on Day 1 for Cycle 7-8\n* Clarithromycin\n\n  500mg PO BID until VGPR or 8 cycles, whichever occurs first\n* Pomalidomide 4mg PO on Days 1-21\n* Dexamethasone 20mg IV as pre-medication on Day 1, 8 40mg PO on the day after daratumumab for Cycle 1 Days 15 and 22 40mg PO pre-daratumumab weekly for Cycle 2-6 20mg PO pre-daratumumab weekly for Cycle 7-8\n\nMaintenance Phase (Cycle 9+): Up to 24 cycles (cycle length of 28 days)\n\n* Daratumumab 1800 mg SC on Day 1\n* Pomalidomide 4mg PO on Day 1-21\n* Dexamethasone 20mg PO pre-daratumumab weekly for Cycles 9 and beyond\n\nDaratumumab SC: Given as 1800mg via injection\n\nClarithromycin: Given as 500mg oral capsule\n\nPomalidomide: Given as 4mg oral capsule\n\nDexamethasone: Given as 20mg IV and 20mg or 40mg oral tablets","id":"BG000","title":"Daratumumab/Clarithromycin/Pomalidomide/Dexamethasone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"IgG Lambda"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"IgG Kappa"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"IgA Lambda"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"IgA Kappa"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"IgD Kappa"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Kappa Free light Chain"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Lambda Free light Chain"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Immunoglobulin Isotype","unitOfMeasure":"Participants"}]}